Form 4: Invivyd CSO Sells Shares After RSU Vesting

Invivyd's Chief Scientific Officer, Robert D. Allen III, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Robert D. Allen III, Chief Scientific Officer of Invivyd, Inc. (IVVD), acquired 99,000 shares of common stock on August 15, 2025, through the vesting of Restricted Stock Units (RSUs).
• Following the vesting, Mr. Allen sold a total of 45,932 shares (18,512 shares on August 18, 2025, and 27,420 shares on August 19, 2025) to satisfy tax withholding obligations.
• These sales were non-discretionary "sell-to-cover" transactions executed under a Rule 10b5-1 plan adopted on February 20, 2025.
• The shares sold on August 18, 2025, had a weighted average price of $0.6502, with prices ranging from $0.5801 to $0.7134.
• The shares sold on August 19, 2025, had a weighted average price of $0.5666, with prices ranging from $0.5524 to $0.6040.
• After these transactions, Mr. Allen beneficially owns 53,068 shares of common stock and 201,000 Restricted Stock Units.
• The RSU award vests over an eighteen-month period, with one-third vesting every six months from the February 15, 2025 grant date, contingent on continuous service.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the vesting of restricted stock units and subsequent "sell-to-cover" sales for tax purposes. These are expected events for executives receiving equity compensation and do not indicate a change in company fundamentals or management's outlook. The continued holding of a significant number of RSUs and common stock by the CSO is a positive.

Positives

• Vesting of 99,000 Restricted Stock Units indicates continued service and performance by the Chief Scientific Officer.
• The sales were pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation and tax obligations.

Negatives

• The Chief Scientific Officer reduced his direct beneficial ownership of common stock by 45,932 shares through sales, even if for tax purposes.
• The sale prices of $0.6502 and $0.5666 are relatively low, potentially reflecting a low stock price for Invivyd at the time of sale.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even for tax purposes, slightly increases the public float. The pre-planned nature of the sales under Rule 10b5-1 mitigates concerns about discretionary selling.
• Employees: The vesting of RSUs is a standard component of executive compensation, which can be a positive for employee morale and retention.

Next Steps

• Future vesting of the remaining 201,000 Restricted Stock Units will occur over an eighteen-month period, with one-third vesting every six months following the February 15, 2025 grant date, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation and tax obligations. The vesting of restricted stock units is a positive for the executive, and the subsequent "sell-to-cover" sales are standard practice and pre-planned, not indicative of a change in company fundamentals or management's confidence. As such, this filing alone does not provide new information that would warrant a change in investment thesis for Invivyd, Inc. Investors should continue to hold based on broader company performance and outlook.

Keywords

Invivyd, IVVD, SEC Form 4, Insider Trading, Stock Sale, RSU Vesting, Restricted Stock Units, Rule 10b5-1, Sell-to-cover, Chief Scientific Officer, Robert D. Allen III, Equity Compensation